<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0011009'>Acute</z:hpo> activation of G protein-coupled receptor 40 (GPR40) by free fatty acids (FFAs) or synthetic GPR40 <z:chebi fb="4" ids="48705">agonists</z:chebi> enhances insulin secretion </plain></SENT>
<SENT sid="1" pm="."><plain>However, it is still a matter of debate whether activation of GPR40 would be beneficial for the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, since <z:hpo ids='HP_0011010'>chronic</z:hpo> exposure to FFAs impairs islet function </plain></SENT>
<SENT sid="2" pm="."><plain>We sought to evaluate the specific role of GPR40 in islets and its potential as a therapeutic target using compounds that specifically activate GPR40 </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: We developed a series of GPR40-selective small-molecule <z:chebi fb="4" ids="48705">agonists</z:chebi> and studied their <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> effects on <z:chebi fb="105" ids="17234">glucose</z:chebi>-dependent insulin secretion (GDIS) in isolated islets, as well as effects on blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels during intraperitoneal <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance tests in <z:mp ids='MP_0002169'>wild-type</z:mp> and GPR40 knockout mice (GPR40(-/-)) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Small-molecule GPR40 <z:chebi fb="4" ids="48705">agonists</z:chebi> significantly enhanced GDIS in isolated islets and <z:mp ids='MP_0005292'>improved glucose tolerance</z:mp> in <z:mp ids='MP_0002169'>wild-type</z:mp> mice but not in GPR40(-/-) mice </plain></SENT>
<SENT sid="5" pm="."><plain>While a 72-h exposure to FFAs in tissue culture significantly impaired GDIS in islets from both <z:mp ids='MP_0002169'>wild-type</z:mp> and GPR40(-/-) mice, similar exposure to the GPR40 <z:chebi fb="4" ids="48705">agonist</z:chebi> did not impair GDIS in islets from <z:mp ids='MP_0002169'>wild-type</z:mp> mice </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, the GPR40 <z:chebi fb="4" ids="48705">agonist</z:chebi> enhanced insulin secretion in perfused pancreata from neonatal <z:chebi fb="1" ids="9288">streptozotocin</z:chebi>-induced diabetic rats and improved <z:chebi fb="105" ids="17234">glucose</z:chebi> levels in mice with high-fat diet-induced <z:hpo ids='HP_0001513'>obesity</z:hpo> acutely and chronically </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: GPR40 does not mediate the <z:hpo ids='HP_0011010'>chronic</z:hpo> toxic effects of FFAs on islet function </plain></SENT>
<SENT sid="8" pm="."><plain>Pharmacological activation of GPR40 may potentiate GDIS in humans and be beneficial for overall <z:chebi fb="105" ids="17234">glucose</z:chebi> control in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>